Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Date:9/8/2009

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies dev
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... in demand for nanotech tools in the coming years, ... New York consulting firm that focuses on nanotechnology. , ... that sales of nanotech tools could double to $1.1 ... on remarkable applications ranging from computer displays to cancer ...
... - Stratatech Corp. has received a $154,000 ... Aging , a division of the National Institutes of ... products for the use in the treatment of chronic skin ... pressure ulcers. , ,It is estimated that in the United ...
... MILWAUKEE -- With the new school semester just ... Marquette University, however, is hoping that illegal Internet downloading ... is the first university working with the Business ... including, Microsoft, Apple and Adobe. The BSA's Define ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Marquette targets illegal downloading 2Marquette targets illegal downloading 3
(Date:5/24/2013)... and other non-coding RNAs are small molecules that ... recent years they have emerged as disease biomarkers. ... origin for cancers of unknown primary origin, determine ... but clinically tractable, diagnostic methods for monitoring miRNA ... In this issue of the Journal of ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3
... 27 ViroPharma Incorporated (Nasdaq: VPHM ) ... Phase 2 study to evaluate the safety, and pharmacokinetics ... (C1 esterase inhibitor [human)] in 24 adolescents and adult ... the U.S. Food and Drug Administration in October ...
... , XIANYANG, China ... Inc. (Nasdaq: BSPM ) ("Biostar" or "the ... B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... new advertising approval from,Shaanxi State Food and Drug ...
... April 27 Mondre Energy, Inc. (MEI), a leading energy ... to address a wide range of energy issues on behalf of the ... Research Program works to ensure that Maryland meets its electricity ... , , ...
Cached Biology News:ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 2Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: